Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956394 | 0.86 | TP53 (0.59) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL5474021 | 0.86 | MEN1 (0.76) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4670795 | 0.86 | TP53 (0.59) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL7095416 | 0.84 | ALDH1A1 (0.68) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL28550900 | 0.84 | TP53 (0.58) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL7095047 | 0.83 | ALDH1A1 (0.67) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL5800630 | 0.83 | KDM4E (0.69) | TP53ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL23252438 | 0.80 | KMT2A (0.55) | KMT2AMEN1NPC1TPSAB1TPSD1 | |
| SCHEMBL3126965 | 0.80 | NPC1 (0.57) | ALDH1A1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL7223688 | 0.80 | MEN1 (0.51) | TP53KMT2AMEN1TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | TP53 2773/4885ALDH1A1 240/4885TSHR 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.